Transcatheter aortic valve implantation (TAVI) is still in early innings here in the U.S. and it seems like new players are constantly entering the game. While the powerhitters in this space so far, companies like Edwards Lifesciences (Irvine, California), which was first to market in the U.S. with its Sapien valve, have the advantage of being the ones that broke open the game, younger companies on deck have the advantage of introducing improved, next-generation technology to the field.